Particularly, higher levels of certain CSF biomarkers (e.g., total tau and amyloid-β) associated with neuronal damage have been shown to act as an accurate predictor of progression from mild cognitive impairment to Alzheimer’s disease [32]. This evidence concerns the gene MAPT and Alzheimer disease.